Cornerstone’s Lixivaptan Falls Prey To Advisory Panel’s Desire For Clinical Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee voted against approval of the vasopressin2 receptor antagonist for treating hyponatremia.